Treatment with either siRNA resulted in a marked reduction in protein expression compared with treatment with Lipofectamine only: the amount of FUS-CHOP protein was reduced by 60% in each myxoid liposarcoma cell line (Figure 2(a) and Supplementary Figure S9(A)), and the amount of eIF4E protein was reduced by 75% in MLS 402 and 82% in MLS 1765 (Figure 2(b) and Supplementary Figure S9(B)) (CHOP: MLS 402, p = 0.004, and MLS 1765, p = 0.045; eIF4E: MLS 402 and MLS 1765, p < 0.0001). The gene discussed is DDIT3; the disease is liposarcoma.